Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
Abstract
Accumulating mutations in the SARS-CoV-2 Spike (S) protein can increase the possibility of immune escape, challenging the present COVID-19 prophylaxis and clinical interventions. Here, 3 receptor binding domain (RBD) specific monoclonal antibodies (mAbs), 58G6, 510A5 and 13G9, with high neutralizing potency blocking authentic SARS-CoV-2 virus displayed remarkable efficacy against authentic B.1.351 virus. Each of these 3 mAbs in combination with one neutralizing Ab recognizing non-competing epitope exhibited synergistic effect against authentic SARS-CoV-2 virus. Surprisingly, structural analysis revealed that 58G6 and 13G9, encoded by the IGHV1-58 and the IGKV3-20 germline genes, both recognized the steric region S470-495 on the RBD, overlapping the E484K mutation presented in B.1.351. Also, 58G6 directly bound to another region S450-458 in the RBD. Significantly, 58G6 and 510A5 both demonstrated prophylactic efficacy against authentic SARS-CoV-2 and B.1.351 viruses in the transgenic mice expressing human ACE2 (hACE2), protecting weight loss and reducing virus loads. These 2 ultrapotent neutralizing Abs can be promising candidates to fulfill the urgent needs for the prolonged COVID-19 pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Subject Area
- Biochemistry (11730)
- Bioengineering (8743)
- Bioinformatics (29179)
- Biophysics (14964)
- Cancer Biology (12080)
- Cell Biology (17399)
- Clinical Trials (138)
- Developmental Biology (9417)
- Ecology (14174)
- Epidemiology (2067)
- Evolutionary Biology (18294)
- Genetics (12233)
- Genomics (16791)
- Immunology (11858)
- Microbiology (28051)
- Molecular Biology (11575)
- Neuroscience (60919)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4955)
- Plant Biology (10422)
- Synthetic Biology (2881)
- Systems Biology (7338)
- Zoology (1650)